HK Stock Market Move | LEPU BIO-B(02157) rose more than 6% in the afternoon, MRG006A combination therapy IND approved, expected to promote precise treatment of liver cancer.

LEPU BIO-B (02157) rose more than 6% in the afternoon, as of the press release, up 5.76% to 4.41 Hong Kong dollars, with a turnover of 33.5741 million Hong Kong dollars. On the news front, on February 26, Lepu Biotechnology announced that its independently developed innovative antibody-drug conjugate MRG006A, in combination with immune checkpoint inhibitors and targeted therapy drugs for late-stage liver cancer patients, has officially been approved by the National Medical Products Administration for clinical trial application. This is the first domestically applied for clinical trial and the first globally to enter the clinical stage of GPC3-targeted ADC drugs. This approval marks a shift from single-drug exploration to combination therapy, and is expected to bring more effective new treatment options for late-stage liver cancer patients. Guolian Minsheng Securities released a research report stating that MRG006A is expected to drive precision treatment of liver cancer. The bank pointed out that Lepu Biotechnology is a leader in the ADC layout, with two ADCs already realizing overseas expansion. MRG006A and MRG007 are both new ADCs developed based on the new generation Hi-TOPi ADC platform, which is expected to increase the company's value.